39
Participants
Start Date
February 7, 2019
Primary Completion Date
April 30, 2022
Study Completion Date
August 30, 2022
recombinant von Willebrand factor
"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
tranexamic acid
"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
State University of New York Upstate Medical Center, Syracuse
University of Pittsburgh and Hemophilia Center Western PA, Pittsburgh
Emory University Afflac Blood Disorders Center, Atlanta
Vanderbilty University, Nashville
Ohio State University Wexner Medical Center, Columbus
Cleveland Clinic Foundation, Cleveland
Henry Ford Hospital Medical Center, Detroit
Michigan State University, East Lansing
Versiti Blood Center of Wisconsin, Milwaukee
Mayo Clinic, Rochester
Washington University St. Louis, St Louis
University of Utah, Salt Lake City
Banner MD Anderson Cancer Center, Gilbert
Cure4thekids Foundation, Las Vegas
Center for Inherited Blood Disorders (CIBD), Orange
University of California San Francisco, San Francisco
Oregon Health and Science University, Portland
Bloodworks Northwest, Seattle
Rutgers Robert Wood Johnson Medical School, New Brunswick
Collaborators (1)
University of North Carolina
OTHER
Duke University
OTHER
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Margaret Ragni
OTHER